13 (Fulvestrant Injection 1)
Fulvestrant Injection, Solution
Product Images NDC 68001-484
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 68001-484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
10 (Fulvestrant Injection 10)
This appears to be a chart showing the progression-free survival probability of patients receiving fulvestrant/palbociclib versus fulvestrant/placebo over a period of 12 months. It includes the number of patients at risk in each group at various time points.*
1 (Fulvestrant Injection 11)
This appears to be a table showing the overall survival probability of patients who were given Fulvestrant and Palbociclib versus patients who were given Fulvestrant and a placebo. The table also shows the number of patients at risk during certain months. However, the text "a8 x% %3 gg3gge" is not readable and there are no further contextual information available.*
Fig 11 (Fulvestrant Injection 12)
Fig 12 (Fulvestrant Injection 13)
This is a survival curve of patients with censored observations under two treatments- fulvestrant plus abemaciclib and fulvestrant plus placebo. The curve shows the survival probability of patients over time in months (Pl i Time) from 0 to 67 months. The observation showed that fulvestrant plus abemaciclib had a higher survival probability than fulvestrant plus placebo. There is an indication of some missing or unreadable characters in the last line of the text.*
Fig 13 (Fulvestrant Injection 14)
1 (Fulvestrant Injection 15)
Fulvestrant Injection Carton (Fulvestrant Injection 16)
Fulvestrant Injection is a prescription medication that comes in two pre-filled syringes containing 250mg/5mL (50 mymu) of the solution, which should be administered through intramuscular injection only. The syringes cannot be split and both are required to receive a dose of 500mg. The medication is intended for use in oncology and is manufactured by OncoPoint. Storage requirements include refrigeration at 2-8 degrees Celsius and protection from light. The rest of the text is not readable.*
Fulvestrant Injection Syringe Label (Fulvestrant Injection 17)
This is a description of a medication called Fulvestrant Injection, which is administered via intramuscular injection and contains 250mg/5mL of medication. The medication is manufactured by Amneal Pharmaceuticals in India and distributed by BluePoint Laboratories. The product must be protected from light and requires the use of both single-dose prefilled syringes to receive the 500mg dose. The NDC number for this medication is 68001-484-86.*
14 (Fulvestrant Injection 2)
15 (Fulvestrant Injection 3)
15 (Fulvestrant Injection 4)
17 (Fulvestrant Injection 5)
16 (Fulvestrant Injection 6)
66 (Fulvestrant Injection 7)
The text provides a graph showing the proportion of patients who remained without the worsening of their medical conditions over time. The information presented in the graph is divided into two groups of patients who received two different doses of a medication called Fulvestrant, 250mg and 500mg respectively. The graph plots the percentage of patients without progression against time measured in months from the start of the treatment. Unfortunately, there is incomplete and insufficient data to draw useful and meaningful conclusions regarding the medication's effectiveness.*
10 (Fulvestrant Injection 8)
Fig 8 (Fulvestrant Injection 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
